• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 497648 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416757237 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416757237 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Vanda Pharmaceuticals Trading Higher on 1.6x Above-Average Volume (VNDA)

Published on Fri, 05/10/2013 - 13:15
By Peter Chu

Vanda Pharmaceuticals's stock is up 1.6% to $5.14 on heavy trading volume. Today's volume of 371,000 shares tops the average 30-day volume of 232,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Vanda Pharmaceuticals share prices have moved between a 52-week high of $5.17 and a 52-week low of $2.92 and are now trading 76% above that low price at $5.14 per share. The 200-day and 50-day moving averages have moved 0.23% higher and 2.04% higher over the past week, respectively.

Potential upside of 65.4% exists for Vanda Pharmaceuticals, based on a current level of $5.14 and analysts' average consensus price target of $8.50. The stock should find initial support at its 50-day moving average (MA) of $4.23 and further support at its 200-day MA of $3.96.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Post Earnings Update: International Pape...

When International Paper (NYSE:IP) reported earnings two weeks ago on November 4th, 201 ...

Protective Life Earnings Review: 19 Days...

Two weeks ago on November 3rd, 2014 Protective Life (NYSE:PL) reported earnings and ana ...

Earnings Look Back: Estee Lauder Is Up 1...

18 days ago, on November 4th, 2014, Estee Lauder (NYSE:EL) reported its earnings. Anal ...

Delek US Holdings Earnings Review: 17 Da...

When Delek US Holdings (NYSE:DK) reported earnings two weeks ago on November 5th, 2014, ...

Earnings Look Back: Stifel Financial Is ...

When Stifel Financial (NYSE:SF) reported earnings two weeks ago on November 6th, 2014, ...

Post Earnings Update: Dean Foods Has Cli...

A week ago on November 10th, 2014 Dean Foods (NYSE:DF) reported earnings and analysts, ...

Earnings Look Back: CF Industries Is Up ...

When CF Industries (NYSE:CF) reported earnings two weeks ago on November 5th, 2014, ana ...

Spectra Energy Earnings Hindsight: Up 0....

When Spectra Energy (NYSE:SE) reported earnings 17 days ago on November 5th, 2014, anal ...